Log In
BCIQ
Print this Print this
 

LJN452

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionNon-bile acid FXR agonist
Molecular Target Farnesoid X receptor (FXR) (NR1H4)
Mechanism of ActionFarnesoid X receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationNon-alcoholic steatohepatitis (NASH)
Indication DetailsTreat non-alcoholic steatohepatitis (NASH)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today